179 related articles for article (PubMed ID: 1687505)
1. Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma.
Poller DN; Galea M; Pearson D; Bell J; Gullick WJ; Elston CW; Blamey RW; Ellis IO
Breast Cancer Res Treat; 1991 Dec; 20(1):3-10. PubMed ID: 1687505
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance?
Barnes DM; Bartkova J; Camplejohn RS; Gullick WJ; Smith PJ; Millis RR
Eur J Cancer; 1992; 28(2-3):644-8. PubMed ID: 1350456
[TBL] [Abstract][Full Text] [Related]
3. Oestrogen receptor expression in ductal carcinoma in situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein.
Poller DN; Snead DR; Roberts EC; Galea M; Bell JA; Gilmour A; Elston CW; Blamey RW; Ellis IO
Br J Cancer; 1993 Jul; 68(1):156-61. PubMed ID: 8100443
[TBL] [Abstract][Full Text] [Related]
4. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO
Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662
[TBL] [Abstract][Full Text] [Related]
5. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
6. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
[TBL] [Abstract][Full Text] [Related]
7. C-erbB-2 oncogene protein in in situ and invasive lobular breast neoplasia.
Porter PL; Garcia R; Moe R; Corwin DJ; Gown AM
Cancer; 1991 Jul; 68(2):331-4. PubMed ID: 1676930
[TBL] [Abstract][Full Text] [Related]
8. Expression of c-erbB3 protein in primary breast carcinomas.
Naidu R; Yadav M; Nair S; Kutty MK
Br J Cancer; 1998 Nov; 78(10):1385-90. PubMed ID: 9823984
[TBL] [Abstract][Full Text] [Related]
9. c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma.
Somerville JE; Clarke LA; Biggart JD
J Clin Pathol; 1992 Jan; 45(1):16-20. PubMed ID: 1346789
[TBL] [Abstract][Full Text] [Related]
10. C-erbB-2 protein and neuroendocrine expression in intraductal carcinomas of the breast.
Lilleng R; Hagmar BM; Nesland JM
Mod Pathol; 1992 Jan; 5(1):41-7. PubMed ID: 1347423
[TBL] [Abstract][Full Text] [Related]
11. [Expression of the c-erbB-2 oncoprotein in mammary Paget's disease. Immunohistochemical study by using 3 antibodies].
Edorh A; Parache RM; Migeon C; N'Sossani B; Rihn B
Pathol Biol (Paris); 1995 Sep; 43(7):584-9. PubMed ID: 8570262
[TBL] [Abstract][Full Text] [Related]
12. c-erbB-2 oncoprotein in screen-detected breast carcinoma: an immunohistological study.
Soomro S; Taylor P; Shepard HM; Feldmann M; Sinnett HD; Shousha S
Int J Cancer; 1993 Aug; 55(1):63-5. PubMed ID: 8102130
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous analysis of c-erbB-2 expression and DNA content in breast cancer using flow cytometry.
Stål O; Sullivan S; Sun XF; Wingren S; Nordenskjöld B
Cytometry; 1994 Jun; 16(2):160-8. PubMed ID: 7924685
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
Allred DC; Clark GM; Molina R; Tandon AK; Schnitt SJ; Gilchrist KW; Osborne CK; Tormey DC; McGuire WL
Hum Pathol; 1992 Sep; 23(9):974-9. PubMed ID: 1355464
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of DNA ploidy and c-erbB-2 oncoprotein overexpression in adenocarcinoma of Barrett's esophagus.
Nakamura T; Nekarda H; Hoelscher AH; Bollschweiler E; Harbeck N; Becker K; Siewert JR; Harbec N [corrected to Harbeck N]
Cancer; 1994 Apr; 73(7):1785-94. PubMed ID: 7907940
[TBL] [Abstract][Full Text] [Related]
16. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression.
Poller DN; Silverstein MJ; Galea M; Locker AP; Elston CW; Blamey RW; Ellis IO
Mod Pathol; 1994 Feb; 7(2):257-62. PubMed ID: 7911998
[TBL] [Abstract][Full Text] [Related]
17. In situ distribution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-beta-subunit.
Kommoss F; Colley M; Hart CE; Franklin WA
Mol Cell Probes; 1990 Feb; 4(1):11-23. PubMed ID: 1969111
[TBL] [Abstract][Full Text] [Related]
18. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features.
Gasparini G; Gullick WJ; Bevilacqua P; Sainsbury JR; Meli S; Boracchi P; Testolin A; La Malfa G; Pozza F
J Clin Oncol; 1992 May; 10(5):686-95. PubMed ID: 1349034
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation.
Ioachim E; Kamina S; Demou A; Kontostolis M; Lolis D; Agnantis NJ
Anticancer Res; 1999; 19(3A):2133-9. PubMed ID: 10470161
[TBL] [Abstract][Full Text] [Related]
20. Neu (c-erbB-2), a tumor marker in carcinoma of the female breast.
Maguire HC; Greene MI
Pathobiology; 1990; 58(6):297-303. PubMed ID: 1981830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]